BMS has submitted phase 3 results from the CheckMate-066 trial, comparing nivolumab with dacarbazine in treatment-naïve advanced melanoma patients.
The PD-1 inhibitor nivolumab (Opdivo), developed by Bristol-Myers Squibb (BMS), has been assigned a priority review by the FDA for use in treatment-naïve patients with advanced melanoma. The drug first passed the FDA’s scrutiny in December 2014, becoming the second immuno-oncology agent from BMS to do so, when it was approved for patients with advanced melanoma who had progressed on ipilimumab (Yervoy) and a B-Raf inhibitor if they harbored the BRaf V600 mutation.1
To support the application, BMS has submitted phase 3 results from the CheckMate-066 trial, in which the performance of treatment-naïve, advanced melanoma patients (with wild type Braf) on nivolumab was compared with that of patients on dacarbazine chemotherapy. Treatment with nivolumab improved overall survival (OS) by 58% and progression free survival (PFS) by 57% compared with dacarbazine. There were indications of a biomarker-based response PD-L1—positive patients had a 70% improvement in OS, while the objective response rate was 52.7% with nivolumab versus 10.8% for dacarbazine.2 “The CheckMate-066 trial marked the first time that a PD-1 immune checkpoint inhibitor showed a survival benefit in a randomized phase 3 trial,” said Michael Giordano, BMS senior vice president and head of development, oncology .1
According to the company’s website, the FDA is required to act by August 27, 2015.References
1. U.S. Food and Drug Administration accepts supplemental biologics license application for Opdivo (nivolumab) in patients with previously untreated advanced [press release]. http://bit.ly/1R9U7Kl. Princeton, NJ: Bristol-Myers Squibb Company; April 4, 2015.
2. Broderick J. FDA grants priority review to frontline nivolumab in melanoma. http://bit.ly/1K97dDv. Published April 30, 2015. Accessed May 22, 2015.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More